Novel epigallocatechin gallate analogs as potential anticancer agents: A patent review (2009 - present)

Expert Opinion on Therapeutic Patents

Volumn 23, Issue 2, 2013, Pages 189-202

  Landis Piwowar, Kristin ^a   Chen, Di ^b   Foldes, Robert ^c   Chan, Tak Hang ^d,e   Dou, Qing Ping ^b  

^a OAKLAND UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Cognovie Inc ^*  (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

Author keywords

Apoptosis; Biotransformation; Combination therapies; EGCG; EGCG analogs; EGCG prodrugs; Proteasome inhibitor; Synthetic EGCG

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CATECHIN; CHLORAMBUCIL; COMPOUND 7; DNA VACCINE; EPICATECHIN; EPICATECHIN GALLATE; EPIGALLOCATECHIN GALLATE; EPIGALLOCATECHIN GALLATE DERIVATIVE; FLUDARABINE; FLUOROURACIL; GREEN TEA EXTRACT; GTP 4; METFORMIN; OLIGOMER; PLACEBO; POLYPHENON E; TRASTUZUMAB; UNCLASSIFIED DRUG;

ACTINIC KERATOSIS; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; CANCER CELL; CELL CYCLE ARREST; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; COMBINATION CHEMOTHERAPY; CONDYLOMA ACUMINATUM; DRUG BIOAVAILABILITY; DRUG POTENTIATION; HUMAN; LUNG TUMOR; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NONHUMAN; OLIGOMERIZATION; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CATECHIN; DRUG DESIGN; HUMANS; MOLECULAR STRUCTURE; PATENTS AS TOPIC; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84872730845     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2013.743993     Document Type: Review

References (77)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29
2. Landis-Piwowar KR, Milacic V, Chen D, et al. The proteasome as a potential target for novel anticancer drugs and chemosensitizers. Drug Resist Updat 2006;9:263-73 (Pubitemid 46357634)
3. Bendell J, Goldberg RM. Targeted agents in the treatment of pancreatic cancer: history and lessons learned. Curr Opin Oncol 2007;19:390-5 (Pubitemid 46883532)
4. Carver JR, Shapiro CL, Ng A, et al. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol 2007;25:3991-4008 (Pubitemid 47477279)
5. Sasazuki S, Tamakoshi A, Matsuo K, et al. Green tea consumption and gastric cancer risk: An evaluation based on a systematic review of epidemiologic evidence among the Japanese population. Jpn J Clin Oncol 2012;42:335-46
6. Yang G, Zheng W, Xiang YB, et al. Green tea consumption and colorectal cancer risk: A report from the Shanghai Men's Health Study. Carcinogenesis 2011;32:1684-8
7. Gupta S, Hussain T, Mukhtar H. Molecular pathway for (-)- epigallocatechin-3-gallate-induced cell cycle arrest and apoptosis of human prostate carcinoma cells. Arch Biochem Biophys 2003;410:177-85 (Pubitemid 36268810)
8. Kemberling JK, Hampton JA, Keck RW, et al. Inhibition of bladder tumor growth by the green tea derivative epigallocatechin-3-gallate. J Urol 2003;170:773-6 (Pubitemid 36999553)
9. Shimizu M, Deguchi A, Lim JT, et al. (-)-Epigallocatechin gallate and polyphenon E inhibit growth and activation of the epidermal growth factor receptor and human epidermal growth factor receptor-2 signaling pathways in human colon cancer cells. Clin Cancer Res 2005;11:2735-46 (Pubitemid 40569476)
10. Shimizu M, Deguchi A, Lim JT, et al. (-)-Epigallocatechin gallate and polyphenon E inhibit growth and activation of the epidermal growth factor receptor and human epidermal growth factor receptor-2 signaling pathways in human colon cancer cells. Clin Cancer Res 2005;11:2735-46 (Pubitemid 40569476)
11. Adhami VM, Siddiqui IA, Ahmad N, et al. Oral consumption of green tea polyphenols inhibits insulin-like growth factor-I-induced signaling in an autochthonous mouse model of prostate cancer. Cancer Res 2004;64:8715-22 (Pubitemid 39552088)
12. Lee HJ, Wang CJ, Kuo HC, et al. Induction apoptosis of luteolin in human hepatoma HepG2 cells involving mitochondria translocation of Bax/Bak and activation of JNK. Toxicol Appl Pharmacol 2005;203:124-31
13. Neuhaus T, Pabst S, Stier S, et al. Inhibition of the vascular-endothelial growth factor-induced intracellular signaling and mitogenesis of human endothelial cells by epigallocatechin-3 gallate. Eur J Pharmacol 2004;483:223-7 (Pubitemid 38068403)
14. Jankun J, Selman SH, Swiercz R, Skrzypczak-Jankun E. Why drinking green tea could prevent cancer. Nature 1997;387:561 (Pubitemid 27248750)
15. Naasani I, Seimiya H, Tsuruo T. Telomerase inhibition, telomere shortening, and senescence of cancer cells by tea catechins. Biochem Biophys Res Commun 1998;249:391-6 (Pubitemid 28431764)
16. Fang MZ, Wang Y, Ai N, et al. Tea polyphenol (-)-epigallocatechin-3- gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res 2003;63:7563-70 (Pubitemid 37466673)
17. Navarro-Peran E, Cabezas-Herrera J, Garcia-Canovas F, et al. The antifolate activity of tea catechins. Cancer Res 2005;65:2059-64 (Pubitemid 40490108)
18. Nam S, Smith DM, Dou QP. Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo. J Biol Chem 2001;276:13322-30
19. Lu H, Meng X, Yang CS. Enzymology of methylation of tea catechins and inhibition of catechol-O-methyltransferase by (-)-epigallocatechin gallate. Drug Metab Dispos 2003;31:572-9 (Pubitemid 36444166)
20. Manach C, Donovan JL. Pharmacokinetics and metabolism of dietary flavonoids in humans. Free Radic Res 2004;38:771-85 (Pubitemid 39077365)
21. Chen Z, Zhu QY, Tsang D, Huang Y. Degradation of green tea catechins in tea drinks. J Agric Food Chem 2001;49:477-82 (Pubitemid 32104551)
22. Bettuzzi S, Corti A, Corvetta S. Mixture of catechins or rather polyphenols extracted from chinese green tea or other vegetables for the prevention of prostate cancer and for the treatment of prostate hypertrophy (BPH). US8044095; 2011
23. Caporali A, Davalli P, Astancolle S, et al. The chemopreventive action of catechins in the TRAMP mouse model of prostate carcinogenesis is accompanied by clusterin over-expression. Carcinogenesis 2004;25:2217-24 (Pubitemid 39534860)
24. Bettuzzi S, Brausi M, Rizzi F, et al. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: A preliminary report from a one-year proof-of-principle study. Cancer Res 2006;66:1234-40 (Pubitemid 43165995)
25. Stockfleth E. Use of a Polyphenol for the Treatment of a Cancerous or Precancerous Lesion of the Skin. US7910138; 2011
26. Buxton I. Polyphenol inhibition of nucleoside diphosphate kinase-B activity and cancer metastasis. US0175834; 2010
27. Lubahn DB, Slusarz A, Shenouda N, Sakla MS. Phytoestrogens an regulators of hedgehog signaling and methods of their use in cancer treatment. US0054517; 2009
28. Yang S, Cheek DJ, Westfall DP, Buxton IL. Purinergic axis in cardiac blood vessels. Agonist-mediated release of ATP from cardiac endothelial cells. Circ Res 1994;74:401-7 (Pubitemid 24064189)
29. Buxton IL, Kaiser RA, Oxhorn BC, Cheek DJ. Evidence supporting the nucleotide axis hypothesis: ATP release and metabolism by coronary endothelium. American journal of physiology. Heart Circ Physiol 2001;281:H1657-66
30. Evangelista M, Tian H, de Sauvage FJ. The hedgehog signaling pathway in cancer. Clin Cancer Res 2006;12:5924-8 (Pubitemid 44703749)
31. Kinzler KW, Bigner SH, Bigner DD, et al. Identification of an amplified, highly expressed gene in a human glioma. Science 1987;236:70-3 (Pubitemid 17056814)
32. Ball ED, Balaian L. Method of increasing efficacy of tumor cell killing using combinations of anti-neoplastic agents. US7977320; 2011
33. Shah MA, Schwartz GK. Cell cycle-mediated drug resistance: An emerging concept in cancer therapy. Clin Cancer Res 2001;7:2168-81 (Pubitemid 32751613)
34. Ishida K, Nishizuka SS, Chiba T, et al. Molecular marker identification for relapse prediction in 5-FU-based adjuvant chemotherapy in gastric and colorectal cancers. PLoS one 2012;7:e43236
35. Satoh T, Sakata Y. S-1 for the treatment of gastrointestinal cancer. Expert Opin Pharmacother 2012;13:1943-59
36. Ciccolini J, Gross E, Dahan L, et al. Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-related severe toxicities: hype or hope? Clin Colorectal Cancer 2010;9:224-8
37. Wei J. Composition for treating cancer and method of using the same. US0068295; 2009
38. Yang XW, Wang XL, Cao LQ, et al. Green tea polyphenol epigallocatechin-3-gallate enhances 5-fluorouracil-induced cell growth inhibition of hepatocellular carcinoma cells. Hepatol Res 2012;42:494-501
39. Norwood AA, Tucci M, Benghuzzi H. A comparison of 5-fluorouracil and natural chemotherapeutic agents, EGCG and thymoquinone, delivered by sustained drug delivery on colon cancer cells. Biomed Sci Instrum 2007;43:272-7 (Pubitemid 46668219)
40. Masuda M, Suzui M, Weinstein IB. Effects of epigallocatechin-3-gallate on growth, epidermal growth factor receptor signaling pathways, gene expression, and chemosensitivity in human head and neck squamous cell carcinoma cell lines. Clin Cancer Res 2001;7:4220-9 (Pubitemid 34044648)
41. Nabhan C, Gartenhaus RB, Tallman MS. Purine nucleoside analogues and combination therapies in B-cell chronic lymphocytic leukemia: dawn of a new era. Leuk Res 2004;28:429-42 (Pubitemid 38453053)
42. Kay NE, Shanafelt TD. Methods of treating hematologic cancers. US0190638; 2012
43. Chang TT, Gulati SC, Chou TC, et al. Synergistic effect of 4-hydroperoxycyclophosphamide and etoposide on a human promyelocytic leukemia cell line (HL-60) demonstrated by computer analysis. Cancer Res 1985;45:2434-9 (Pubitemid 15024403)
44. Wu T, Hung C. Anticancer Combination therapies. US20100330105; 2010
45. Kim TW, Hung CF, Ling M, et al. Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins. J Clin Invest 2003;112:109-17 (Pubitemid 38056382)
46. Cheng WF, Hung CF, Pai SI, et al. Repeated DNA vaccinations elicited qualitatively different cytotoxic T lymphocytes and improved protective antitumor effects. J Biomed Sci 2002;9:675-87
47. Chung JE, Kurisawa M, Yang YY, Zhuo L. Aldehyde conjugated flavonoid preparations. US7858080; 2010
48. Ying JY, Chung JE, Kurisawa M, Ng SP. Method of delivering an anti-cancer agent to a cell. US0044992; 2011
49. Dou QP, Chan T, Smith DM. Polyphenol proteasome inhibitors, synthesis, and methods of use. US8058310; 2012
50. Chow HH, Cai Y, Alberts DS, et al. Phase I pharmacokinetic study of tea polyphenols following single-dose administration of epigallocatechin gallate and polyphenon E. Cancer Epidemiol Biomarkers Prev 2001;10:53-8 (Pubitemid 32106044)
51. Dou QP, Chan T, Smith DM. Polyphenol proteasome inhibitors, synthesis, and methods of use. US7767711; 2010
52. Dou QP, Chan T, Smith DM. Polyphenol proteasome inhibitors, synthesis, and methods of use. US0029067; 2012
53. Wu AH, Tseng CC, Van Den Berg D, Yu MC. Tea intake, COMT genotype, and breast cancer in Asian-American women. Cancer Res 2003;63:7526-9 (Pubitemid 37413498)
54. Landis-Piwowar KR, Wan SB, Wiegand RA, et al. Methylation suppresses the proteasome-inhibitory function of green tea polyphenols. J Cell Physiol 2007;213:252-60 (Pubitemid 47378814)
55. Golden EB, Lam PY, Kardosh A, et al. Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors. Blood 2009;113:5927-37
56. Chan T, Dou QP. Polyphenol compounds for inhibiting proteasome and uses thereof. US0152210; 2011
57. Pamu S, Chen D, Morin F, et al. Inhibitory effect of bortezomib on human multiple myeloma cells when combined with epigallocatechin-gallate (EGCG) analogs. Med Chem Comm 2012;3:229-32
58. Liu B, Fan Z, Edgerton SM, et al. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle 2009;8:2031-40
59. Alimova IN, Liu B, Fan Z, et al. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 2009;8:909-15
60. Zakikhani M, Dowling R, Fantus IG, et al. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006;66:10269-73 (Pubitemid 44799743)
61. Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 2009;69:7507-11
62. Chen D, Pamu S, Cui Q, et al. Novel epigallocatechin gallate (EGCG) analogs activate AMP-activated protein kinase pathway and target cancer stem cells. Bioorg Med Chem 2012;20:3031-7
63. Chan T, Lam W, Chow LM, et al. Epigallocatechin gallate derivatives for inhibiting proteasome. US20080176931; 2008
64. Chan T, Lam W, Chow LM, et al. Epigallocatechin gallate derivatives for inhibiting proteasome. US8193377; 2012
65. Kazi A, Daniel KG, Smith DM, et al. Inhibition of the proteasome activity, a novel mechanism associated with the tumor cell apoptosis-inducing ability of genistein. Biochem Pharmacol 2003;66:965-76 (Pubitemid 37083593)
66. Lambert JD, Lee MJ, Lu H, et al. Epigallocatechin-3-gallate is absorbed but extensively glucuronidated following oral administration to mice. J Nutr 2003;133:4172-7 (Pubitemid 37505494)
67. Chow HH, Cai Y, Hakim IA, et al. Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. Clin Cancer Res 2003;9:3312-19 (Pubitemid 37082725)
68. Yang CS, Chen L, Lee MJ, et al. Blood and urine levels of tea catechins after ingestion of different amounts of green tea by human volunteers. Cancer Epidemiol Biomarkers Prev 1998;7:351-4 (Pubitemid 28354149)
69. Landis-Piwowar KR, Huo C, Chen D, et al. A novel prodrug of the green tea polyphenol (-)-epigallocatechin-3-gallate as a potential anticancer agent. Cancer Res 2007;67:4303-10 (Pubitemid 46815078)
70. Lambert JD, Sang S, Hong J, et al. Peracetylation as a means of enhancing in vitro bioactivity and bioavailability of epigallocatechin-3-gallate. Drug Metab Dispos 2006;34:2111-16 (Pubitemid 44837773)
71. Lee SC, Chan WK, Lee TW, et al. Effect of a prodrug of the green tea polyphenol (-)-epigallocatechin-3-gallate on the growth of androgen-independent prostate cancer in vivo. Nutr Cancer 2008;60:483-91
72. Chiou YS, Ma NJ, Sang S, et al. Peracetylated (-)-epigallocatechin-3- gallate (AcEGCG) potently suppresses dextran sulfate sodium-induced colitis and colon tumorigenesis in mice. J Agric Food Chem 2012;60:3441-51
73. Fereidoon S, Zhong Y. Fatty acid derivatives of catechins and methods of their use. WO123942; 2011
74. Mori S, Miyake S, Kobe T, et al. Enhanced anti-influenza A virus activity of (-)-epigallocatechin-3-O-gallate fatty acid monoester derivatives: effect of alkyl chain length. Bioorg Med Chem Lett 2008;18:4249-52
75. Matsumura K, Kaihatsu K, Mori S, et al. Enhanced antitumor activities of (-)-epigallocatechin-3-O-gallate fatty acid monoester derivatives in vitro and in vivo. Biochem Biophys Res Commun 2008;377:1118-22
76. Bettuzzi S, Brausi M, Rizzi F, et al. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: A preliminary report from a one-year proof-of-principle study. Cancer Res 2006;66:1234-40 (Pubitemid 43165995)
77. Shanafelt TD, Call TG, Zent CS, et al. Phase 2 trial of daily, oral polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemia. Cancer 2012; [Epub ahead of print]